What are the phantom share units reported by Viemed Healthcare CFO on this Form 4?

The filing shows 3,265 phantom share units vesting under Viemed’s Phantom Share Unit Plan. Each phantom share is economically equivalent to one common share and is settled for cash, paired with acquisition and simultaneous surrender of an equal number of common shares to the company.

Viemed Healthcare (VMD) CFO logs RSU and phantom share unit vesting in Form 4

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity on January 29, 2026. A block of 9,794 restricted stock units converted into the same number of common shares, and 3,265 cash-settled phantom share units were settled into common shares under the company’s plans.

To cover tax obligations from the restricted stock vesting, 2,679 common shares were withheld by Viemed at a per‑share value of $7.48. In connection with the phantom share settlement, 3,265 common shares were delivered to and simultaneously surrendered back to the company for cash. After these transactions, Trae directly owned 105,638 common shares.

Insider Trade Summary

13,059 shares exercised/converted

Mixed 6 txns

Insider Fitzgerald Trae

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	9,794	$0.00	--
Exercise	Phantom Share Units	3,265	$0.00	--
Exercise	Common Shares	9,794	$0.00	--
Tax Withholding	Common Shares	2,679	$7.48	$20K
Exercise	Common Shares	3,265	$0.00	--
Disposition	Common Shares	3,265	$7.48	$24K

Holdings After Transaction: Restricted Stock Units — 9,794 shares (Direct); Phantom Share Units — 3,264 shares (Direct); Common Shares — 108,317 shares (Direct)

Footnotes (1)

Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units. Per share value is based on the market closing price of the common shares for January 29, 2026. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash. Restricted Stock Units (RSUs) granted to reporting person on January 29, 2024, which vest in three equal annual installments beginning on the first anniversary of the grant date. Represents an award granted on January 29, 2024 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

02/02/2026 - 05:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Trae

(Last)

(First)

(Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE

70508

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	01/29/2026		M		9,794	A	⁽¹⁾	108,317	D
Common Shares	01/29/2026		F		2,679⁽²⁾	D	$7.48⁽³⁾	105,638	D
Common Shares	01/29/2026		M		3,265	A	⁽⁴⁾	108,903	D
Common Shares	01/29/2026		D		3,265	D	$7.48⁽³⁾	105,638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/29/2026		M			9,794	⁽⁵⁾	01/29/2027	Common Shares	9,794	$0	9,794	D
Phantom Share Units	⁽⁴⁾	01/29/2026		M			3,265	⁽⁶⁾	01/29/2027	Common Shares	3,265	$0	3,264	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.

3. Per share value is based on the market closing price of the common shares for January 29, 2026.

4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.

5. Restricted Stock Units (RSUs) granted to reporting person on January 29, 2024, which vest in three equal annual installments beginning on the first anniversary of the grant date.

6. Represents an award granted on January 29, 2024 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Viemed Healthcare CFO Fitzgerald Trae report on Form 4?

Fitzgerald Trae reported vesting and settlement of equity awards, not an open-market trade. Restricted stock units and phantom share units converted into common shares, with some shares withheld or surrendered back to Viemed Healthcare to satisfy tax and cash-settlement obligations.

How many Viemed Healthcare (VMD) restricted stock units vested for the CFO?

9,794 restricted stock units vested for the CFO, each converting into one common share. These RSUs were originally granted on January 29, 2024 and are scheduled to vest in three equal annual installments beginning on the first anniversary of the grant date.

Were any Viemed Healthcare shares withheld for taxes in this insider filing?

Yes. 2,679 common shares were withheld by Viemed Healthcare to cover the CFO’s tax obligations from restricted stock unit vesting. The per‑share value used for this withholding was $7.48, based on the common shares’ market closing price on January 29, 2026.

How many Viemed Healthcare common shares does the CFO own after these transactions?

Following the reported equity award vesting, withholding, and phantom share settlement, the CFO directly owned 105,638 Viemed Healthcare common shares. This figure reflects the net position after shares were both acquired through awards and surrendered or withheld on the same date.

Do the Viemed Healthcare Form 4 transactions involve open-market buying or selling?

The reported activity reflects equity award vesting, tax withholding, and cash-settled phantom share transactions, not open-market trades. Shares were acquired through conversion of restricted stock and phantom units, then some were withheld or surrendered back to Viemed Healthcare for tax and cash settlement purposes.